A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease

A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease

Background and Aims: Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis are pressing public health problems occurring alongside the rising prevalence of obesity and diabetes. This feasibility study explored the use of a novel prescription di...

Full description

Bibliographic Details
Main Authors:	Naim Alkhouri, Katherine Edwards, Mark Berman, Heather Finn, Rafael Escandon, Paul Lupinacci, Nicole Guthrie, Angie Coste, Jesus Topete, Mazen Noureddin
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	Gastro Hep Advances
Subjects:	Metabolic Dysfunction-Associated Steatotic Liver Disease Metabolic Dysfunction-Associated Steatohepatitis Prescription Digital Therapeutic Cognitive Behavioral Therapy Lifestyle Modification
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772572323001437

Similar Items

Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver diseaseKey points
by: Guillaume Henin, et al.
Published: (2024-02-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
by: Wayne Eskridge, et al.
Published: (2023-09-01)

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors
by: Yoshihisa Takahashi, et al.
Published: (2023-10-01)

Kaempferol Improves Cardiolipin and ATP in Hepatic Cells: A Cellular Model Perspective in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Akiko Sakurai, et al.
Published: (2024-02-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
by: Katharina Staufer, et al.
Published: (2023-07-01)

Emerging therapies for MASLD and their impact on plasma lipids
by: Madison Nguyen, et al.
Published: (2024-03-01)

Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
by: Byeong Geun Song, et al.
Published: (2024-03-01)

Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease
by: Zehra N. Kocas-Kilicarslan, et al.
Published: (2024-01-01)

Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma
by: Han Wang, et al.
Published: (2024-03-01)

Evaluation of Human Hepatocyte Drug Metabolism Carrying High-Risk or Protection-Associated Liver Disease Genetic Variants
by: Lanuza A. P. Faccioli, et al.
Published: (2023-08-01)

What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside
by: Pojsakorn Danpanichkul, et al.
Published: (2024-01-01)

Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Shuangshuang Zhao, et al.
Published: (2024-01-01)

The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis
by: Yvonne Burmeister, et al.
Published: (2023-12-01)

Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Soyeon Shin, et al.
Published: (2023-12-01)

Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice
by: Mara Caputo, et al.
Published: (2024-02-01)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
by: Gi-Ae Kim, et al.
Published: (2023-10-01)

Alterations of the duodenal mucosal microbiome in patients with metabolic dysfunction-associated steatotic liver disease
by: Mengting Ren, et al.
Published: (2024-04-01)

Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs
by: Baoqiang Zhu, et al.
Published: (2023-11-01)

Low thyroid function is associated with metabolic dysfunction‐associated steatotic liver disease
by: Shuo Wang, et al.
Published: (2024-02-01)

Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation
by: Byeong Hyun Min, et al.
Published: (2024-12-01)

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
by: Joo Hyun Oh, et al.
Published: (2024-04-01)

Targeting nuclear receptors for NASH/MASH: From bench to bedside
by: Rohit A. Sinha
Published: (2024-03-01)

Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Avneet Singh, et al.
Published: (2024-02-01)

Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project
by: Katarzyna Nabrdalik, et al.
Published: (2023-11-01)

Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence
by: Jingli Gao, et al.
Published: (2024-03-01)

Molecular Mechanisms of Curcumin in the Pathogenesis of Metabolic Dysfunction Associated Steatotic Liver Disease
by: Marta Guariglia, et al.
Published: (2023-12-01)

Risk of binge eating disorder in patients with metabolic dysfunction-associated steatotic liver disease
by: Lucia Brodosi, et al.
Published: (2023-12-01)

Steatotic liver disease among lean and non-lean individuals in Southern Lao PDR: a cross-sectional study of risk factors
by: Anousin Homsana, et al.
Published: (2024-12-01)

Identification and validation of hub genes expressed in ulcerative colitis with metabolic dysfunction-associated steatotic liver disease
by: Yupei Liu, et al.
Published: (2024-03-01)

Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of metabolic dysfunction-associated steatotic liver disease in a Chinese population
by: Chenbing Liu, et al.
Published: (2024-04-01)

An Optimized Strategy Based on Conventional Ultrasound for Diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Xiongcai Feng, et al.
Published: (2023-11-01)

New insights into metabolic dysfunction-associated steatotic liver disease and oxidative balance score
by: Lei Peng, et al.
Published: (2024-01-01)

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
by: Hidekatsu Yanai, et al.
Published: (2023-10-01)

Melatonin Prevents Alcohol- and Metabolic Dysfunction- Associated Steatotic Liver Disease by Mitigating Gut Dysbiosis, Intestinal Barrier Dysfunction, and Endotoxemia
by: Karli R. LeFort, et al.
Published: (2023-12-01)

Clinical Predictive Score for Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Prediabetes Using Transient Elastography
by: Nutthachoke Mahachai, et al.
Published: (2023-12-01)

Association between diet soft drink consumption and metabolic dysfunction-associated steatotic liver disease: findings from the NHANES
by: Yanrui Wu, et al.
Published: (2023-11-01)

Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic
by: Guocheng Rao, et al.
Published: (2023-11-01)

2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes
by: Amélio F. Godoy-Matos, et al.
Published: (2024-01-01)

Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018
by: Zongbiao Tan, et al.
Published: (2023-11-01)

Intestinal Pgc1α ablation protects from liver steatosis and fibrosis
by: Elena Piccinin, et al.
Published: (2023-11-01)